Fig. 3 | Scientific Reports

Fig. 3

From: The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study

Fig. 3

Quantitative determination of the protective effect of selected antiallergic aye drop formulations against dehydration in Human Primary Conjunctival Epithelial Cells (HConEpiC). (a) Cell viability after 17-hour treatment with EDF 1, EDF 2, EDF 3, and EDF 6. (b) Cell viability after 17-hour treatment with EDF 3, EDF 4, EDF 5, EDF 7, EDF 8, and EDF 9. Cell viability is expressed as percentage (%) relative to the positive control. Results are presented as means ± standard deviations. Statistically significant differences compared to the negative control (untreated and dehydrated control cells): *p < 0.05. Statistically significant differences compared to EDF 3 (bilastine 0.6%): #p < 0.05. EDF 1 (0.025% ketotifen fumarate); EDF 2 (0.05% azelastine hydrochloride); EDF 3 (0.6% bilastine); EDF 4 (0.222% olopatadine hydrochloride); EDF 5 (0.05% azelastine hydrochloride); EDF 6 (0.776% olopatadine hydrochloride); EDF 7 (0.05% levocabastine hydrochloride); EDF 8 (0.1% olopatadine hydrochloride); EDF 9 (0.025% ketotifen fumarate).

Back to article page